Replimune Group (NASDAQ:REPL) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Replimune Group (NASDAQ:REPL) in a report released on Friday morning,Benzinga reports. They currently have a $17.00 price objective on the stock.

A number of other brokerages have also recently weighed in on REPL. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Roth Mkm began coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $17.00.

Replimune Group Trading Down 11.2 %

NASDAQ REPL opened at $13.26 on Friday. The firm’s fifty day moving average price is $11.59 and its 200 day moving average price is $9.76. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The company has a market capitalization of $907.25 million, a price-to-earnings ratio of -4.35 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, sell-side analysts expect that Replimune Group will post -3.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its stake in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Replimune Group in the second quarter valued at $57,000. Arizona State Retirement System purchased a new stake in shares of Replimune Group during the 2nd quarter worth $108,000. Quest Partners LLC boosted its position in shares of Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Replimune Group in the 3rd quarter valued at about $133,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.